Formosa Laboratories Inc
TWSE:4746

Watchlist Manager
Formosa Laboratories Inc Logo
Formosa Laboratories Inc
TWSE:4746
Watchlist
Price: 73.6 TWD 0.96% Market Closed
Market Cap: 8.9B TWD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Formosa Laboratories Inc stock under the Base Case scenario is 108.92 TWD. Compared to the current market price of 73.6 TWD, Formosa Laboratories Inc is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
108.92 TWD
Undervaluation 32%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
59
vs Industry
39
Median 3Y
2.4
Median 5Y
2.1
Industry
2.4
Forward
1.8
More Details
22.5
P/E
P/E
Price to Earnings
22.5
vs History
27
vs Industry
3
Median 3Y
21.6
Median 5Y
12
Industry
20.5
Forward
13.6
More Details
10.8
P/OCF
P/OCF
Price to OCF
10.8
vs History
85
vs Industry
27
Median 3Y
14.8
Median 5Y
14.5
Industry
15.4
More Details
192.5
P/FCFE
P/FCFE
Price to FCFE
192.5
vs History
4
vs Industry
19
Median 3Y
21.1
Median 5Y
-8.9
Industry
22.6
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
33
vs Industry
45
Median 3Y
1.2
Median 5Y
1.1
Industry
2
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
98
vs Industry
35
Median 3Y
2.8
Median 5Y
2.8
Industry
2.5
Forward
2
More Details
4.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.8
vs History
98
vs Industry
29
Median 3Y
7
Median 5Y
7.6
Industry
4.9
More Details
8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8
vs History
98
vs Industry
30
Median 3Y
13
Median 5Y
16
Industry
12.6
Forward
7.6
More Details
13.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.8
vs History
69
vs Industry
21
Median 3Y
19.2
Median 5Y
19.8
Industry
15.6
Forward
13.2
More Details
11.8
EV/OCF
EV/OCF
Enterprise Value to OCF
11.8
vs History
98
vs Industry
25
Median 3Y
16.8
Median 5Y
18
Industry
13.9
More Details
43
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
43
vs History
25
vs Industry
9
Median 3Y
43
Median 5Y
-9.9
Industry
17.7
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
40
vs Industry
50
Median 3Y
1
Median 5Y
0.9
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Formosa Laboratories Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
TW
Formosa Laboratories Inc
TWSE:4746
8.9B TWD 1.9 22.5 8 13.8
US
Eli Lilly and Co
NYSE:LLY
793.6B USD 17.6 74.9 43.5 48
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
393.8B USD 4.4 28 13.1 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 8.1 23.3 15.3 17.4
CH
Roche Holding AG
SIX:ROG
246.5B CHF 4.2 21.4 11.9 14.2
US
Merck & Co Inc
NYSE:MRK
235.8B USD 3.7 13.8 9.3 10.9
UK
AstraZeneca PLC
LSE:AZN
180B GBP 4.3 33.1 127.1 194.1
CH
Novartis AG
SIX:NOVN
202B CHF 4.4 19.1 11.6 14.8
IE
Endo International PLC
LSE:0Y5F
166.1B USD 71.6 -56.8 265.3 665.3
US
Pfizer Inc
NYSE:PFE
148.9B USD 2.3 18.5 8.8 12.5
P/E Multiple
Earnings Growth PEG
TW
Formosa Laboratories Inc
TWSE:4746
Average P/E: 28.3
22.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
74.9
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
23.3
19%
1.2
CH
Roche Holding AG
SIX:ROG
21.4
16%
1.3
US
Merck & Co Inc
NYSE:MRK
13.8
17%
0.8
UK
AstraZeneca PLC
LSE:AZN
33.1
36%
0.9
CH
Novartis AG
SIX:NOVN
19.1
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TW
Formosa Laboratories Inc
TWSE:4746
Average EV/EBITDA: 396.4
8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.5
30%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
15%
1
CH
Roche Holding AG
SIX:ROG
11.9
8%
1.5
US
Merck & Co Inc
NYSE:MRK
9.3
9%
1
UK
AstraZeneca PLC
LSE:AZN
127.1
9%
14.1
CH
Novartis AG
SIX:NOVN
11.6
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
265.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.8
3%
2.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TW
Formosa Laboratories Inc
TWSE:4746
Average EV/EBIT: 1 701
13.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
17.4
16%
1.1
CH
Roche Holding AG
SIX:ROG
14.2
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.9
12%
0.9
UK
AstraZeneca PLC
LSE:AZN
194.1
21%
9.2
CH
Novartis AG
SIX:NOVN
14.8
8%
1.9
IE
E
Endo International PLC
LSE:0Y5F
665.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.5
10%
1.3

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 240,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.